Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域_老虎社区_美港股上老虎

Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域

智通财经网04-07

4月6日，Neurocrine Biosciences(NBIX.US)周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics(SLNO.US)，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。据悉，Neurocrine Biosciences提出以每股53美元收购Soleno Therapeutics股份，较该股上一交易日收盘价溢价约34%。截至收盘，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2625693674?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2026-04-07 06:05","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2625693674","market":"hk","top_or_hot":-1,"title":"Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域","media":"智通财经网","content":"<div>\n<p>4月6日，Neurocrine Biosciences(NBIX.US)周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics(SLNO.US)，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。据悉，Neurocrine Biosciences提出以每股53美元收购Soleno Therapeutics股份，较该股上一交易日收盘价溢价约34%。截至收盘，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1425299.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine斥资29亿美元收购Soleno，进军代谢疾病领域\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-07 06:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1425299.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月6日，Neurocrine Biosciences(NBIX.US)周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics(SLNO.US)，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。据悉，Neurocrine Biosciences提出以每股53美元收购Soleno Therapeutics股份，较该股上一交易日收盘价溢价约34%。截至收盘，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1425299.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLNO","symbol_name":"Soleno Therapeutics","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1425299.html","article_id":"2625693674","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625693674","pubTimestamp":1775513144,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"Neurocrine Biosciences周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SLNO":"Soleno Therapeutics","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","NBIX":"神经分泌生物科学","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC"},"translate_title":"Neurocrine (NBIX.US) Jumps into Metabolic Diseases with $2.9 Billion Acquisition of Soleno (SLNO.US)","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/8976daf97a80d1d184bdfeca3d7883d1","symbols_score_info":{"SLNO":1.5,"NBIX":1.5},"content_text":"4月6日，Neurocrine Biosciences(NBIX.US)周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics(SLNO.US)，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。据悉，Neurocrine Biosciences提出以每股53美元收购Soleno Therapeutics股份，较该股上一交易日收盘价溢价约34%。截至收盘，Soleno Therapeutics股价飙涨逾32%。该交易使Neurocrine Biosciences获得药物Vykat XR的使用权，该药是美国首个获批用于治疗与Prader-Willi syndrome相关暴食症(hyperphagia)的药物，在2025年3月获批后约九个月内实现约1.9亿美元销售额。暴食症，即强烈且持续的饥饿感，可导致严重肥胖以及身体、心理和行为方面的问题。根据美国政府数据，该综合征发病率约为每2万至3万名新生儿中出现1例，美国约有2万名患者受到影响。BMO Capital Markets分析师Evan Seigerman中表示，考虑到竞争和监管障碍，相比Neurocrine Biosciences仍处于临床前测试阶段的自研肥胖治疗候选药物，此次交易提供了一条“更为合理的进入代谢疾病领域路径”。分析师估算称，Vykat XR预计今年将带来4.5亿美元销售额，全球销售额将在2030年代中期超过20亿美元。Neurocrine Biosciences表示，这笔预计将在未来90天内完成的交易将通过现有现金支付，并补充称公司计划举借少量可提前偿还的债务。","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}